31.41

1.63% -0.565

Agios Pharmaceuticals Inc (AGIO)

Overview News Price History Option Chain Financials Discussions Forecast

Agios Pharmaceuticals Inc stock is traded at $31.41, with a volume of 53,180. It is down -1.63% in the last 24 hours and down -5.53% over the past month. Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.

Previous Close:

$31.98

Open:

$32

24h Volume:

53,180

Relative Volume:

0.06

Market Cap:

$1.83B

Revenue:

$32.87M

Net Income/Loss:

$674.31M

P/E Ratio:

2.7654

EPS:

11.36

Net Cash Flow:

$-330.11M

1W Performance:

-7.42%

1M Performance:

-5.53%

6M Performance:

-32.62%

1Y Performance:

+4.87%

1-Day Range:

$31.37

$32.50

1-Week Range:

$31.33

$34.47

52-Week Range:

$27.14

$62.58

Agios Pharmaceuticals Inc Stock (AGIO) Company Profile

Name

Agios Pharmaceuticals Inc

Sector

Healthcare (1172)

Industry

Biotechnology (680)

Phone

617-649-8600

Address

88 SIDNEY STREET, CAMBRIDGE, MA

Employee

488

Twitter

@AgiosPharma

Next Earnings Date

2024-10-31

Latest SEC Filings

AGIO's Discussions on Twitter

Compare AGIO with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
AGIO Agios Pharmaceuticals Inc	31.38	1.83B	32.87M	674.31M	-330.11M	11.36
VRTX Vertex Pharmaceuticals Inc	498.54	130.96B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	678.02	75.53B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	577.05	35.07B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	240.79	31.72B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	249.47	26.76B	3.32B	-860.46M	-1.04B	-8.32

Agios Pharmaceuticals Inc Stock (AGIO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-24-25	Initiated	H.C. Wainwright	Buy
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Oct-10-24	Resumed	Raymond James	Outperform
Sep-27-24	Downgrade	Leerink Partners	Outperform → Market Perform
Feb-08-24	Initiated	Cantor Fitzgerald	Overweight
Feb-03-23	Initiated	Piper Sandler	Overweight
Nov-17-22	Upgrade	Goldman	Sell → Neutral
Jul-27-22	Upgrade	SVB Leerink	Mkt Perform → Outperform
Dec-03-21	Initiated	BofA Securities	Buy
Jul-30-21	Downgrade	Goldman	Neutral → Sell
Jul-01-21	Initiated	Raymond James	Mkt Perform
Jun-10-21	Initiated	H.C. Wainwright	Buy
Mar-01-21	Downgrade	JP Morgan	Overweight → Neutral
Mar-01-21	Upgrade	SVB Leerink	Mkt Perform → Outperform
Feb-26-21	Downgrade	SVB Leerink	Outperform → Mkt Perform
Oct-22-20	Upgrade	Barclays	Equal Weight → Overweight
Mar-04-20	Initiated	Barclays	Equal Weight
Nov-26-19	Initiated	Cantor Fitzgerald	Overweight
Sep-23-19	Upgrade	Guggenheim	Neutral → Buy
May-23-19	Resumed	Goldman	Neutral
Feb-15-19	Upgrade	SVB Leerink	Mkt Perform → Outperform
Sep-25-18	Initiated	Leerink Partners	Mkt Perform
May-23-18	Initiated	Citigroup	Buy
Apr-11-18	Reiterated	Credit Suisse	Outperform
Feb-15-18	Reiterated	Needham	Buy
Feb-15-18	Reiterated	SunTrust	Buy
Sep-15-17	Initiated	RBC Capital Mkts	Outperform
Aug-10-17	Reiterated	Needham	Buy
Aug-08-17	Reiterated	SunTrust	Buy
Aug-02-17	Upgrade	Leerink Partners	Mkt Perform → Outperform
Jun-26-17	Downgrade	Janney	Buy → Neutral
Jan-17-17	Upgrade	Oppenheimer	Perform → Outperform
Oct-24-16	Initiated	Needham	Buy
Jun-13-16	Upgrade	JP Morgan	Neutral → Overweight
May-18-16	Reiterated	SunTrust	Buy

View All

Agios Pharmaceuticals Inc Stock (AGIO) Latest News

Mar 12, 2025

Agios Pharmaceuticals at Barclays Conference: Strategic Advances in Rare Disease Treatments - Investing.com UK

Mar 12, 2025

Mar 10, 2025

Agios Pharmaceuticals Announces Inducement Equity Awards for New Executive - GuruFocus.com

Mar 05, 2025

Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Corporate Development & Strategy Officer - The Manila Times

Mar 05, 2025

Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Corporate - EIN News

Mar 05, 2025

Celldex Therapeutics and Agios Pharmaceuticals to Present at March 2025 Investor Conferences - Barchart

Mar 05, 2025

Meet Agios' New Strategy Chief: Inside the $2M+ Executive Compensation Deal - StockTitan

Mar 05, 2025

Mar 04, 2025

Agios Pharmaceuticals chief commercial officer sells $59,742 in stock By Investing.com - Investing.com South Africa

Mar 04, 2025

Agios Pharmaceuticals chief commercial officer sells $59,742 in stock - Investing.com India

Mar 04, 2025

Agios Pharmaceuticals CEO sells shares worth $460,135 - Investing.com

Mar 04, 2025

Agios to Present at Upcoming Investor Conferences - The Manila Times

Mar 04, 2025

Where to Hear Agios Management Next Month: Key Investor Conferences Revealed - StockTitan

Mar 04, 2025

Mar 01, 2025

Insmed, Agios rise; DraftKings, Atlantica fall, Tuesday, 5/28/2024 - Star Tribune

Mar 01, 2025

Is Agios Pharmaceuticals, Inc. (AGIO) the Best Small-Cap Stock to Buy Now? - Insider Monkey

Mar 01, 2025

Y Intercept Hong Kong Ltd Acquires Shares of 45,817 Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - MarketBeat

Mar 01, 2025

What is HC Wainwright's Estimate for AGIO Q1 Earnings? - MarketBeat

Mar 01, 2025

Feb 28, 2025

Earnings call transcript: Agios Pharm Q4 2024 beats EPS forecast, stock rises - MSN

Feb 28, 2025

10 Best Small-Cap Stocks to Buy Now - Insider Monkey

Feb 28, 2025

Gilbert Cisneros conducts multiple transactions in stocks including Agios Pharmaceuticals and Airbnb - MSN

Feb 28, 2025

Feb 27, 2025

Sickle Cell Disease Market Growth Projections 2024-2034: - openPR

Feb 27, 2025

Q4 Earnings Estimate for AGIO Issued By HC Wainwright - MarketBeat

Feb 27, 2025

Feb 26, 2025

Venturi Wealth Management LLC Takes Position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - Defense World

Feb 26, 2025

What is HC Wainwright’s Estimate for AGIO Q4 Earnings? - Defense World

Feb 26, 2025

Agios Bolsters Coffers With $1.1 Bln Milestone Payments Following FDA Approval Of Vorasidenib - RTTNews

Feb 26, 2025

Feb 24, 2025

H.C. Wainwright sets $58 target on Agios Pharma stock with Buy rating By Investing.com - Investing.com South Africa

Feb 24, 2025

H.C. Wainwright starts Agios Pharmaceuticals coverage with 'buy' - TradingView

Feb 24, 2025

H.C. Wainwright sets $58 target on Agios Pharma stock with Buy rating - Investing.com India

Feb 24, 2025

Feb 21, 2025

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Short Interest Down 6.0% in January - MarketBeat

Feb 21, 2025

Feb 20, 2025

Agios to Present at the TD Cowen 45th Annual Healthcare Conference on March 3, 2025 - The Manila Times

Feb 20, 2025

Why Agios Pharmaceuticals' (NASDAQ:AGIO) Earnings Are Weaker Than They Seem - Simply Wall St

Feb 20, 2025

Rare Disease Leader Agios Takes Center Stage at Major Healthcare ConferenceKey Details Inside - StockTitan

Feb 20, 2025

Feb 19, 2025

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q4 2024 Earnings Call Transcript - MSN

Feb 19, 2025

Agios Pharmaceuticals (NASDAQ:AGIO) Downgraded by StockNews.com to "Sell" - MarketBeat

Feb 19, 2025

Feb 17, 2025

Agios' Q4 Loss Wider Than Expected, Pyrukynd Drives Revenues - MSN

Feb 17, 2025

Agios Pharmaceuticals (NASDAQ: AGIO) Board Member Resignation: David P. Schenkein Steps Down - Defense World

Feb 17, 2025

Here's Why Agios Stock Plummeted More Than 20% on Monday - MSN

Feb 17, 2025

Feb 16, 2025

Agios (AGIO) Q1 Earnings Surpass, Sales Miss Estimates - MSN

Feb 16, 2025

Feb 15, 2025

Agios Pharmaceuticals (AGIO) Reports Q4 Loss, Tops Revenue Estimates - MSN

Feb 15, 2025

Agios Pharmaceuticals price target lowered to $74 from $75 at Scotiabank - Yahoo Finance

Feb 15, 2025

Agios Pharmaceuticals announces board resignation - MSN

Feb 15, 2025

Long Term Trading Analysis for (AGIO) - Stock Traders Daily

Feb 15, 2025

Feb 14, 2025

Agios Pharmaceuticals: Liver Toxicity Issues May Threaten Thalassemia Approval (Rating Downgrade) - Seeking Alpha

Feb 14, 2025

Positive Phase III ACTIVATE-Kids study of Agios’ mitapivat - The Pharma Letter

Feb 14, 2025

Agios Pharmaceuticals Full Year 2024 Earnings: Beats Expectations - Yahoo Finance

Feb 14, 2025